Search results
People also ask
Who is Eric Pierce?
Who is Dr Pierce?
Who is Steven Pierce?
Who is Jeff Pierce?
Eric A. Pierce, MD, PhD. William F. Chatlos Professor of Ophthalmology. Research Area (s): Inherited Retinal Degenerations , Ocular Genomics. Harvard Medical School. Director, Ocular Genomics Institute. Mass Eye and Ear. Director, Berman-Gund Laboratory for the Study of Retinal Degenerations. Senior Scientist. Profiles: OGI Profile. OGI Website.
Eric A. Pierce, MD, PhD. Massachusetts Eye and Ear. Physician and Surgeon. Harvard Medical School. William F. Chatlos Professor of Ophthalmology. Contact. Phone: 617-573-3621. Specialties. Inherited Retinal Disorders. Retina. New Patients. Currently Accepting. Research Profile. Where I Provide Care. Boston. Main Campus. 243 Charles Street,
Dr. Pierce’s research program is focused on identifying new IRD disease genes, investigating the mechanism by which mutations in the identified genes lead to blindness, and using this information about disease pathogenesis to develop rational therapies to prevent vision loss. Email: eric_pierce@meei.harvard.edu
About Eric Pierce, MD, PhD. Dr. Eric Pierce is a full-time clinician scientist. He is Director of the Ocular Genomics Institute at Mass. Eye and Ear, and the William F. Chatlos Professor of Ophthalmology at Harvard Medical School. As a group, retinal degenerations are a common cause of blindness.
- (617) 523-7900
- Q: Can You Describe The Nature of Your Research and Your Team’S Work?
- Q: What Impact Do You Hope Your Work Will Have on Patient Care?
- Q: Is The Eventual Hope to Restore Or Preserve Your Patients’ Vision?
- Q: What Do You See as The Future of Gene and Cell Therapy?
- Q: Why Do You Think Mass General Brigham Is Such A Great Place to Do Research?
Pierce: I was recruited back to Harvard Medical School in 2011 to found and establish the Ocular Genomics Institute (OGI). Our mission is to bring precision medicine to the treatment of inherited eye disorders; this includes conducting research on the genetic causality of inherited eye disorders, and then using that information to develop genetical...
Pierce: One of the great things about working at Mass Eye and Ear as a clinician-scientist, is that we're doing translational medicine. We see patients with inherited eye diseases, we work to identify the genetic causes of their disorders, and then we use that information to develop genetic therapies. The whole idea of the OGI is to bring these tre...
Pierce: Yes, based on experience with gene therapies that have been deployed to date, there is evidence that both prevention of further vision loss, and potential restoration of some vision is possible with genetic therapies for inherited retinal degenerations. It’s exciting to work with patients whose vision is notably impaired and hear them descr...
Pierce: I think we're going to see expanded use of what we're now calling traditional gene therapy. AAV-based gene augmentation therapies can be used for approximately two-thirds of patients of inherited retinal degenerations. For the remaining one third of patients the genes that harbor the mutations which cause their disease are too large for AAV...
Pierce: We're excited to be one of the premier centers for studying the genetics of and developing genetic therapies for inherited eye diseases resulting from the investment that the Mass Eye and Ear and Mass General Brigham has made in our Ocular Genomics Institute. The support from the Hospital and from the Institution has really allowed us to gr...
Eric Pierce – Ocular Genomics Institute. Home. Team. Eric Pierce. Meet the team. Eric Pierce OGI Director eric_pierce@meei.harvard.edu. Pierce Lab. Dr. Eric Pierce received his Ph.D. in Biochemistry from the University of Wisconsin-Madison and his M.D. from Harvard Medical School.
GS Robinson, EA Pierce, SL Rook, E Foley, R Webb, LE Smith. Proceedings of the National Academy of Sciences 93 (10), 4851-4856. , 1996. 490. 1996. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a ….
